Antonio Llombart-Cussac MD, PhD, discussed extended follow-up results from the phase 2 PARSIFAL study combining the CDK4/6 inhibitor palbociclib with either fulvestrant or letrozole.
Antonio Llombart-Cussac MD, PhD, discussed extended follow-up results from the phase 2 PARSIFAL study combining the CDK4/6 inhibitor palbociclib with either fulvestrant or letrozole.
Antonio Llombart-Cussac MD, PhD,...